These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 20705798)

  • 1. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension.
    Cartin-Ceba R; Swanson K; Iyer V; Wiesner RH; Krowka MJ
    Chest; 2011 Jan; 139(1):109-14. PubMed ID: 20705798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension.
    Halank M; Knudsen L; Seyfarth HJ; Ewert R; Wiedemann B; Kolditz M; Höffken G; Hoeper MM
    Z Gastroenterol; 2011 Sep; 49(9):1258-62. PubMed ID: 21887662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
    Preston IR; Burger CD; Bartolome S; Safdar Z; Krowka M; Sood N; Ford HJ; Battarjee WF; Chakinala MM; Gomberg-Maitland M; Hill NS
    J Heart Lung Transplant; 2020 May; 39(5):464-472. PubMed ID: 32008947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secure Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat Portopulmonary Hypertension Minimizing Each Adverse Effect.
    Muraoka H; Imamura T; Hatano M; Maki H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2015; 56(4):471-3. PubMed ID: 26084462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
    Galiè N; Olschewski H; Oudiz RJ; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Gerber MJ; Dufton C; Wiens BL; Rubin LJ;
    Circulation; 2008 Jun; 117(23):3010-9. PubMed ID: 18506008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
    Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
    BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation.
    Raevens S; De Pauw M; Reyntjens K; Geerts A; Verhelst X; Berrevoet F; Rogiers X; Troisi RI; Van Vlierberghe H; Colle I
    Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):495-502. PubMed ID: 23242127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
    Oudiz RJ; Galiè N; Olschewski H; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Harrison BC; Despain D; Dufton C; Rubin LJ;
    J Am Coll Cardiol; 2009 Nov; 54(21):1971-81. PubMed ID: 19909879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambrisentan therapy for pulmonary arterial hypertension.
    Galié N; Badesch D; Oudiz R; Simonneau G; McGoon MD; Keogh AM; Frost AE; Zwicke D; Naeije R; Shapiro S; Olschewski H; Rubin LJ
    J Am Coll Cardiol; 2005 Aug; 46(3):529-35. PubMed ID: 16053970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral pulmonary vasoactive drugs achieve hemodynamic eligibility for liver transplantation in portopulmonary hypertension.
    Legros L; Chabanne C; Camus C; Fournet M; Houssel-Debry P; Latournerie M; Jezequel C; Rayar M; Boudjema K; Guyader D; Bardou-Jacquet E
    Dig Liver Dis; 2017 Mar; 49(3):301-307. PubMed ID: 27840058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
    Hassoun PM; Zamanian RT; Damico R; Lechtzin N; Khair R; Kolb TM; Tedford RJ; Hulme OL; Housten T; Pisanello C; Sato T; Pullins EH; Corona-Villalobos CP; Zimmerman SL; Gashouta MA; Minai OA; Torres F; Girgis RE; Chin K; Mathai SC
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1102-10. PubMed ID: 26360334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.
    Klinger JR; Oudiz RJ; Spence R; Despain D; Dufton C
    Am J Cardiol; 2011 Jul; 108(2):302-7. PubMed ID: 21545989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Portopulmonary hypertension: Results from a 10-year screening algorithm.
    Krowka MJ; Swanson KL; Frantz RP; McGoon MD; Wiesner RH
    Hepatology; 2006 Dec; 44(6):1502-10. PubMed ID: 17133488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
    Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.
    Blalock SE; Matulevicius S; Mitchell LC; Reimold S; Warner J; Peshock R; Torres F; Chin KM
    J Card Fail; 2010 Feb; 16(2):121-7. PubMed ID: 20142023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ambrisentan for the management of pulmonary arterial hypertension.
    Cheng JW
    Clin Ther; 2008 May; 30(5):825-33. PubMed ID: 18555930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
    Shapiro S; Pollock DM; Gillies H; Henig N; Allard M; Blair C; Anglen C; Kohan DE
    Am J Cardiol; 2012 Nov; 110(9):1373-7. PubMed ID: 22858181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
    Hoeper MM; McLaughlin VV; Barberá JA; Frost AE; Ghofrani HA; Peacock AJ; Simonneau G; Rosenkranz S; Oudiz RJ; White RJ; Miller KL; Langley J; Harris JHN; Blair C; Rubin LJ; Vachiery JL
    Lancet Respir Med; 2016 Nov; 4(11):894-901. PubMed ID: 27745818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of portopulmonary hypertension patients after liver transplantation.
    Khaderi S; Khan R; Safdar Z; Stribling R; Vierling JM; Goss JA; Sussman NL
    Liver Transpl; 2014 Jun; 20(6):724-7. PubMed ID: 24648168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.